About: Besifloxacin     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # O'Brien TP: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22729919 # Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19492955 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
http://linked.open...drugbank/halfLife
  • The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours. (en)
http://linked.open...ugbank/indication
  • Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius* (en)
sameAs
Title
  • Besifloxacin (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Besifloxacin is a bactericidal fluroquinolone-type antibiotic that inhibits bacterial enzymes, DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell devision is impaired. Inhibiting these two targets also slows down development of resistance. (en)
http://linked.open...y/drugbank/patent
http://linked.open...outeOfElimination
  • N/A (en)
http://linked.open.../drugbank/synonym
  • Besifloxacin (en)
  • SS734 (en)
http://linked.open...drugbank/toxicity
  • LD50, rat: >2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness. (en)
http://linked.open...umeOfDistribution
  • Not absorbed into the systemic (en)
http://linked.open.../drug/hasAHFSCode
http://linked.open...nk/proteinBinding
  • None (en)
http://linked.open...ogy/drugbank/salt
  • (en)
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...logy/drugbank/pKa
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects. (en)
http://linked.open.../affectedOrganism
  • Gram negative and gram positive bacteria (en)
  • Streptococcus pneumoniae (en)
  • Pseudomonas aeruginosa (en)
  • Haemophilus influenzae (en)
  • Staphylococcus aureus (en)
  • Staphylococcus epidermidis (en)
  • Aerococcus viridans (en)
  • Corynebacterium pseudodiphtheriticum (en)
  • Corynebacterium sp. G (en)
  • Corynebacterium striatum (en)
  • Moraxella catarrhalis (en)
  • Moraxella lacunata (en)
  • Staphylococcus hominis (en)
  • Staphylococcus lugdunensis (en)
  • Staphylococcus warneri (en)
  • Streptococcus mitis (en)
  • Streptococcus oralis (en)
  • Streptococcus salivarius (en)
http://linked.open...casRegistryNumber
  • 141388-76-3 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...rugbank/clearance
  • N/A (en)
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software